Page last updated: 2024-10-28

ifosfamide and Cystitis

ifosfamide has been researched along with Cystitis in 62 studies

Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.

Research Excerpts

ExcerptRelevanceReference
"Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity."9.08Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995)
"Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem."8.84Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. ( Korkmaz, A; Oter, S; Topal, T, 2007)
"Acrolein is the main toxic metabolite of ifosfamide (IFO) that causes urothelial damage by oxidative stress and inflammation."8.31[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10. ( Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN, 2023)
"Hemorrhagic cystitis (HC) is the major dose-limiting adverse effect of the clinical use ifosfamide (IFOS)."7.96α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. ( Almeida, FRC; Cunha, FVM; Gonçalves, RLG; Lima-Júnior, RCP; Lopes, ME; Medeiros, JVR; Nogueira, KM; Oliveira, CPC; Oliveira, FA; Oliveira, LSA; Pereira, VMP; Rezende, DC; Sousa, DP; Sousa, IJO; Sousa-Neto, BPS; Souza, LKM; Wong, DVT, 2020)
"Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites."7.91IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. ( Alouffi, A; Banskota, N; Falcone, FH; Hsieh, MH; Ishida, K; Jardetzky, TS; Le, L; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, R, 2019)
"Hemorrhagic cystitis is an important dose limiting side effect of ifosfamide based cancer chemotherapy."7.81Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice. ( Alencar, VT; Brito, GA; Cunha, FQ; Leite, CA; Lima-Júnior, RC; Magalhães, PJ; Melo, DL; Melo, PH; Mota, JM; Mourão, LT; Ribeiro, RA; Santos, AA; Wong, DV, 2015)
"We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis."7.78Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. ( Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV, 2012)
"Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium."7.77Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011)
"Ifosfamide (IFS) is an antineoplastic alkylating agent whose major side effect is hemorrhagic cystitis (HC)."7.74Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. ( Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML, 2007)
"Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)."7.74Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008)
"Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)."7.72Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003)
") in cyclophosphamide (CYP) and ifosfamide (IFS) induced hemorrhagic cystitis (HC)."7.72Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. ( Brito, GA; Costa, AC; Cunha, AN; Filho, JN; Macêdo, FY; Ribeiro, RA; Silveira, ER; Vieira, MM, 2004)
"We investigated the participation of nitric oxide in ifosfamide induced hemorrhagic cystitis in mice, and the involvement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in the induction of nitric oxide production in this model."7.71Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. ( Brito, GA; Campos, MC; Cunha, FQ; Figueiredo, FC; Freitas, HC; Ribeiro, RA; Santos, CC, 2002)
"Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent."7.69Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."7.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment."7.67Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985)
"One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial."7.67Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."7.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"To prevent hemorrhagic cystitis induced by ifosfamide, continuous bladder irrigation with 3,000 ml."7.66Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. ( Fujita, J; Kakizoe, T; Matsumoto, K; Murase, T, 1981)
"Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers."5.48Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. ( Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT, 2018)
"The incidence of IFO-induced HC may be associated with the dosage of IFO."5.43A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016)
"Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity."5.08Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995)
"The use of oxazaphosphorines (cyclophosphamide, ifosfamide) in the treatment of numerous neoplastic disorders is associated with their essential adverse effect in the form of hemorrhagic cystitis, which considerably limits the safety and efficacy of their pharmacotherapy."4.88Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention . ( Dobrek, Ł; Thor, PJ, 2012)
"Cyclophosphamide (CP) and ifosfamide (IF) are widely used antineoplastic agents, but their side-effect of hemorrhagic cystitis (HC) is still encountered as an important problem."4.84Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. ( Korkmaz, A; Oter, S; Topal, T, 2007)
"Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis."4.82Side effects of ifosfamide. ( Klastersky, J, 2003)
"Acrolein is the main toxic metabolite of ifosfamide (IFO) that causes urothelial damage by oxidative stress and inflammation."4.31[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10. ( Clementino, M; da Silva, JA; de Freitas, TM; Ferreira, FCS; Havt, A; Lima, AAM; Lima, MA; Martins, DS; Mota, MRL; Queiroga, ML; Ribeiro, SA; Rodrigues, FAP; Silva, DO; Veras, HN, 2023)
"Hemorrhagic cystitis (HC) is the major dose-limiting adverse effect of the clinical use ifosfamide (IFOS)."3.96α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice. ( Almeida, FRC; Cunha, FVM; Gonçalves, RLG; Lima-Júnior, RCP; Lopes, ME; Medeiros, JVR; Nogueira, KM; Oliveira, CPC; Oliveira, FA; Oliveira, LSA; Pereira, VMP; Rezende, DC; Sousa, DP; Sousa, IJO; Sousa-Neto, BPS; Souza, LKM; Wong, DVT, 2020)
"Ifosfamide and other oxazaphosphorines can result in hemorrhagic cystitis, a constellation of complications caused by acrolein metabolites."3.91IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. ( Alouffi, A; Banskota, N; Falcone, FH; Hsieh, MH; Ishida, K; Jardetzky, TS; Le, L; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, R, 2019)
"Hemorrhagic cystitis is an important dose limiting side effect of ifosfamide based cancer chemotherapy."3.81Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice. ( Alencar, VT; Brito, GA; Cunha, FQ; Leite, CA; Lima-Júnior, RC; Magalhães, PJ; Melo, DL; Melo, PH; Mota, JM; Mourão, LT; Ribeiro, RA; Santos, AA; Wong, DV, 2015)
"We investigated whether interleukin-4 (IL-4) is present and capable of reducing inflammatory changes seen in ifosfamide-induced hemorrhagic cystitis."3.78Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis. ( Brito, GA; Cunha, FQ; Freitas, HC; Lima, RC; Macedo, FY; Mourão, LT; Oriá, RB; Ribeiro, RA; Vale, ML; Wong, DV, 2012)
"Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium."3.77Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011)
" Groups (N = 6-8) were submitted to right or left paw edema (PE) with carrageenan (100 microg) or Dextran (200 microg), hemorrhagic cystitis with ifosfamide (200 mg/kg, ip) or gastric injury (GI) with indomethacin (20 mg/kg, vo)."3.75Hind limb ischemic preconditioning induces an anti-inflammatory response by remote organs in rats. ( Gomes, AS; Loiola, RT; Ribeiro, RA; Rocha, EL; Simão, AF; Souza Filho, MV; Souza, MH, 2009)
"Ifosfamide (IFS) is an antineoplastic alkylating agent whose major side effect is hemorrhagic cystitis (HC)."3.74Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. ( Batista, CK; Brito, GA; Cunha, FQ; Leitão, BT; Mota, JM; Ribeiro, RA; Souza, MH; Souza, ML, 2007)
"Hemorrhagic cystitis (HC) is a limiting side effect of chemotherapy with ifosfamide (IFS)."3.74Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats. ( Almeida, PR; Baltazar, F; Brito, GA; Ferreira, FV; Macedo, FY; Ribeiro, RA; Schmitt, FC; Távora, F, 2008)
") in cyclophosphamide (CYP) and ifosfamide (IFS) induced hemorrhagic cystitis (HC)."3.72Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats. ( Brito, GA; Costa, AC; Cunha, AN; Filho, JN; Macêdo, FY; Ribeiro, RA; Silveira, ER; Vieira, MM, 2004)
"Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)."3.72Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003)
" Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy."3.71U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002)
"We investigated the participation of nitric oxide in ifosfamide induced hemorrhagic cystitis in mice, and the involvement of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta in the induction of nitric oxide production in this model."3.71Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice. ( Brito, GA; Campos, MC; Cunha, FQ; Figueiredo, FC; Freitas, HC; Ribeiro, RA; Santos, CC, 2002)
"Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent."3.69Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1996)
"To prevent hemorrhagic cystitis, mesna is typically injected intravenously (i."3.69Combined intravenous and oral mesna in outpatients treated with ifosfamide. ( Goodman, TL; Goren, MP; McKenna, LM, 1997)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."3.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"This study examined the characteristics of urinary bladder lesions (cystitis) induced by ifosfamide (IF), an antitumor agent, and their inhibition by mesna in rats."3.68[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna]. ( Kasai, H; Matsui, S; Muraoka, Y; Nara, H; Watanabe, H, 1990)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."3.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"One hundred twenty-four children and young adults with recurrent tumors, predominantly sarcomas, were treated with the combination of ifosfamide, etoposide, and the uroprotector, mesna (2-mercaptoethane sulphonate), in a phase II trial."3.67Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. ( Forquer, R; Jarosinski, P; Kinsella, TJ; Magrath, I; Miser, JS; Triche, TJ; Tsokos, M; Wesley, R, 1987)
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment."3.67Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985)
"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis."3.67Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication. ( Hilgard, P; Pohl, J; Stekar, J, 1989)
"Urotoxic side effects, especially hemorrhagic cystitis, have so far been a limiting factor in the therapeutic use of cyclophosphamide (Endoxan), ifosfamide (Holoxan), and trofosfamide (Ixoten)."3.66Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. ( Brock, N; Pohl, J; Stekar, J, 1981)
"To prevent hemorrhagic cystitis induced by ifosfamide, continuous bladder irrigation with 3,000 ml."3.66Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation. ( Fujita, J; Kakizoe, T; Matsumoto, K; Murase, T, 1981)
"Twenty-five women with advanced breast carcinoma refractory to first-line chemotherapy entered a phase II trial to evaluate the efficacy of ifosfamide and carboplatin."2.68Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma. ( Herman, RL; Kelley, AS; Muggia, FM; Russell, CA; Spicer, DV; Turrill, M, 1995)
" This review summarizes dosing schedules and the incidence of hematuria in 47 clinical studies, in which oral mesna was given to at least 1,986 patients who received more than 6,475 courses of ifosfamide."2.39Oral administration of mesna with ifosfamide. ( Goren, MP, 1996)
"Novel therapeutic options to treat hemorrhagic cystitis are needed."1.51IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis. ( Akinwale, J; Alouffi, A; Falcone, FH; Hsieh, MH; Jardetzky, TS; Le, LH; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, RS, 2019)
"Ifosfamide (IFO) is an antineoplastic drug that is commonly used to treat gynecological and breast cancers."1.48Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide. ( Alencar, NMN; Almeida, PRC; Alves, APNN; Araújo, LCNC; Bingana, RD; Cunha, FQ; Dornelas-Filho, AF; Lima-Júnior, RCP; Melo, AT; Nobre, LMS; Nour, ML; Pereira, VBM; Pinto, FMM; Silva, CMS; Silva, PGB; Silva, RO; Souza, MHLP; Wanderley, CWS; Wong, DVT, 2018)
"The incidence of IFO-induced HC may be associated with the dosage of IFO."1.43A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016)
" The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide."1.32Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004)
" Ifosfamide, although itself the effective antineoplastic drug useful in situations which have proved refractory to cyclophosphamide therapy, has the side-effect toxicities caused by its metabolities that pose clinically a very real problem."1.30Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. ( Konarski, L; Kowalski, P; Kuśnierczyk, H; Radzikowski, C, 1997)

Research

Studies (62)

TimeframeStudies, this research(%)All Research%
pre-199020 (32.26)18.7374
1990's14 (22.58)18.2507
2000's13 (20.97)29.6817
2010's13 (20.97)24.3611
2020's2 (3.23)2.80

Authors

AuthorsStudies
Ferreira, FCS1
Clementino, M1
Rodrigues, FAP1
Veras, HN1
Martins, DS1
Queiroga, ML1
Lima, MA1
Silva, DO1
de Freitas, TM1
Ribeiro, SA1
Mota, MRL1
da Silva, JA1
Lima, AAM1
Havt, A1
Gonçalves, RLG1
Cunha, FVM1
Sousa-Neto, BPS1
Oliveira, LSA1
Lopes, ME1
Rezende, DC1
Sousa, IJO1
Nogueira, KM1
Souza, LKM1
Medeiros, JVR1
Wong, DVT2
Pereira, VMP1
Lima-Júnior, RCP2
Sousa, DP1
Oliveira, CPC1
Almeida, FRC1
Oliveira, FA1
Kamal, M1
Govil, A1
Anand, M1
Abu Jawdeh, BG1
Shah, S1
Dornelas-Filho, AF1
Pereira, VBM1
Nobre, LMS1
Melo, AT1
Silva, CMS1
Wanderley, CWS1
Nour, ML1
Araújo, LCNC1
Silva, RO1
Pinto, FMM1
Bingana, RD1
Souza, MHLP1
Alencar, NMN1
Silva, PGB1
Alves, APNN1
Almeida, PRC1
Cunha, FQ6
Schaeffer, EM1
Mbanefo, EC2
Le, L1
Zee, R1
Banskota, N1
Ishida, K1
Pennington, LF2
Odegaard, JI2
Jardetzky, TS2
Alouffi, A2
Falcone, FH2
Hsieh, MH3
Zee, RS1
Le, LH1
Akinwale, J1
Leite, CA1
Alencar, VT1
Melo, DL1
Mota, JM2
Melo, PH1
Mourão, LT4
Wong, DV3
Magalhães, PJ3
Santos, AA2
Brito, GA9
Lima-Júnior, RC2
Ribeiro, RA11
Saito, Y1
Kumamoto, T1
Makino, Y1
Tamai, I1
Ogawa, C1
Terakado, H1
Matz, EL1
Lawson, M1
Vasilaras, A1
De Vries, A1
Mactaggart, P1
Nicol, D1
Glezerman, IG1
Souza Filho, MV1
Loiola, RT1
Rocha, EL1
Simão, AF1
Gomes, AS1
Souza, MH3
Macedo, FY5
Palheta, RC1
Jucá, DM1
Lima, RC2
Neto, Jde S1
Freitas, HC2
Oriá, RB1
Vale, ML2
de Siqueira, RJ1
Freire, WB1
Vasconcelos-Silva, AA1
Fonseca-Magalhães, PA1
Lima, FJ1
Brito, TS1
Lahlou, S1
Pereira, LM1
Bem, AX1
Teixeira, CG1
Grassi, LS1
Medeiros, RP1
Marques-Neto, RD1
Callado, RB1
Aragão, KS1
Dobrek, Ł1
Thor, PJ1
Cohen, MH1
Dagher, R1
Griebel, DJ1
Ibrahim, A1
Martin, A1
Scher, NS1
Sokol, GH1
Williams, GA1
Pazdur, R1
Klastersky, J1
Vieira, MM2
Belarmino-Filho, JN1
Nery, EA1
Filho, JN1
Costa, AC1
Cunha, AN1
Silveira, ER1
Kopp, HG1
Kanz, L1
Hartmann, JT1
Batista, CK1
Souza, ML1
Leitão, BT1
Korkmaz, A1
Topal, T1
Oter, S1
Baltazar, F1
Almeida, PR1
Távora, F1
Ferreira, FV1
Schmitt, FC1
Mukouda, K1
Morikawa, E1
Hasegawa, K1
Noumi, K1
Ohmura, T1
Mishima, Y1
Kawamoto, M1
Inagaki, A1
Kamitsuna, A1
Yamakido, M1
Nishimoto, Y1
Koyama, T1
Katsuta, S1
Watson, RA1
Brock, N5
Pohl, J5
Stekar, J5
Czownicki, Z1
Utracka-Hutka, B1
Slavik, M1
Saiers, JH1
Fujita, J1
Matsumoto, K1
Kakizoe, T1
Murase, T1
Shinozaki, T1
Matsushita, M1
Kusawake, H1
Watanabe, H2
Arita, S1
Chigira, M1
Udagawa, E1
Matsumoto, S1
Kawaguchi, N1
Manabe, J1
Kuroda, H1
Shimoji, T1
Turrill, M1
Spicer, DV1
Kelley, AS1
Herman, RL1
Russell, CA1
Muggia, FM1
Sakuma, H1
Satoh, T2
Matsumoto, E1
Kanno, H1
Watanabe, M1
Kikuta, A1
Suzuki, H1
Ishii, T1
Umeda, T1
Kitoh, M1
Tatezaki, S1
Ingle, JN1
Krook, JE1
Mailliard, JA1
Hartmann, LC1
Wieand, HS1
Goren, MP2
Markman, M1
Kennedy, A1
Webster, K1
Kulp, B1
Peterson, G1
Belinson, J1
Kuśnierczyk, H1
Konarski, L1
Kowalski, P1
Radzikowski, C1
McKenna, LM1
Goodman, TL1
Bonfante, V1
Viviani, S1
Devizzi, L1
Di Russo, A1
Di Nicola, M1
Magni, M1
Matteucci, P1
Grisanti, S1
Valagussa, P1
Bonadonna, G1
Gianni, AM1
Campos, MC1
Santos, CC1
Figueiredo, FC1
Brühl, P1
Hoefer-Janker, H1
Scheef, W1
Vahlensieck, W1
Niemeyer, U1
Scheffler, G1
Marti, C1
Steiner, R1
Viollier, AF1
Frustaci, S1
Foladore, S1
De Pascale, A1
Freschi, A1
Lo Re, G1
Sorio, R1
Errante, D1
Monfardini, S1
Iwasaku-Fujimoto, M1
Fujiwara, F1
Todo, S1
Morioka, Y1
Imashuku, S1
Antman, KH2
Elias, A1
Ryan, L1
Muraoka, Y1
Matsui, S1
Nara, H1
Kasai, H1
Hilgard, P1
Sakurai, M1
Saijo, N1
Shinkai, T1
Eguchi, K1
Sasaki, Y1
Tamura, T1
Sano, T1
Suemasu, K1
Jett, JR1
Andriole, GL1
Sandlund, JT1
Miser, JS2
Arasi, V1
Linehan, M1
Magrath, IT1
Kinsella, TJ1
Triche, TJ1
Tsokos, M1
Jarosinski, P1
Forquer, R1
Wesley, R1
Magrath, I1
Brade, W1
Seeber, S1
Herdrich, K1
Montella, D1
Rosenbaum, C1
Schwen, M1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty: A Pilot Randomized Control Trial[NCT02406131]40 participants (Anticipated)Interventional2018-04-30Suspended (stopped due to logistic issues - no available scans for participants at the moment need to postponed starting dates)
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]Phase 2/Phase 337 participants (Actual)Interventional2016-03-31Completed
Late Effects of Treatment in Survivors of Pediatric Sarcomas[NCT00006515]39 participants (Actual)Observational2000-11-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for ifosfamide and Cystitis

ArticleYear
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
    Urology, 2017, Volume: 100

    Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Mesna

2017
Urological implications of cyclophosphamide and ifosfamide.
    Scandinavian journal of urology and nephrology, 2008, Volume: 42, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Cystitis; Humans; Ifosfamide;

2008
Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention .
    Postepy higieny i medycyny doswiadczalnej (Online), 2012, Sep-10, Volume: 66

    Topics: Animals; Antineoplastic Agents, Alkylating; Chemoprevention; Cyclophosphamide; Cystitis; Cytoprotect

2012
Side effects of ifosfamide.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Cystitis; Drug Interactions; Heart; Hemorrhage; H

2003
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
    Cell biology and toxicology, 2007, Volume: 23, Issue:5

    Topics: Acrolein; Antineoplastic Agents; Cell Death; Cyclophosphamide; Cystitis; Cytokines; DNA Damage; Enzy

2007
Oral administration of mesna with ifosfamide.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Drug Administrat

1996
Comparative activity of ifosfamide and cyclophosphamide.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cystitis; Humans; Ifosfam

1986

Trials

8 trials available for ifosfamide and Cystitis

ArticleYear
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Nowotwory, 1981, Volume: 30, Issue:4

    Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol

1981
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1995
Phase II clinical trial of carboplatin, ifosfamide, with oral mesna for metastatic breast carcinoma.
    Cancer investigation, 1995, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl

1995
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    American journal of clinical oncology, 1995, Volume: 18, Issue:6

    Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cystitis; Drug Administration Schedule; D

1995
High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
    European journal of haematology. Supplementum, 2001, Volume: 64

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystitis; Female; Granulocyte Colony-Stimulat

2001
Feasibility and efficacy of arginine 2-mercaptoethanesulfonate (ARGIMESNA) in the prevention of hemorragic cystitis from ifosfamide (IFO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Adolescent; Adult; Aged; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Male; Mesna; Middle Aged

1992
Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Child; Chil

1990
The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Japanese journal of clinical oncology, 1986, Volume: 16, Issue:2

    Topics: Adult; Aged; Clinical Trials as Topic; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Lung Neopla

1986

Other Studies

47 other studies available for ifosfamide and Cystitis

ArticleYear
[8] and [10]-Gingerol reduces urothelial damage in ifosfamide-induced hemorrhagic cystitis via JAK/STAT/FOXO signaling pathway via IL-10.
    Naunyn-Schmiedeberg's archives of pharmacology, 2023, Volume: 396, Issue:8

    Topics: Animals; Cystitis; Female; Hemorrhage; Ifosfamide; Inflammation; Interleukin-10; Mesna; Mice; Signal

2023
α-Phellandrene attenuates tissular damage, oxidative stress, and TNF-α levels on acute model ifosfamide-induced hemorrhagic cystitis in mice.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:10

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Cyclohexane Monoterpenes; Cyst

2020
Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; BK Virus; Cystitis; Hemorrhage; Humans;

2018
Neutrophils contribute to the pathogenesis of hemorrhagic cystitis induced by ifosfamide.
    International immunopharmacology, 2018, Volume: 62

    Topics: Animals; Antineoplastic Agents, Alkylating; Cystitis; Drug Therapy, Combination; Female; Hemorrhage;

2018
Re: Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-Induced Hemorrhagic Cystitis.
    The Journal of urology, 2018, Volume: 200, Issue:4

    Topics: Cyclophosphamide; Cystitis; Hemorrhage; Humans; Ifosfamide; Protective Agents

2018
IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways.
    Scientific reports, 2019, 02-07, Volume: 9, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Cystitis; Cytokines; Egg Proteins; Gene Expression Profiling; Hel

2019
IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis.
    American journal of physiology. Renal physiology, 2019, 06-01, Volume: 316, Issue:6

    Topics: Administration, Intravesical; Animals; Basophils; Cell Line; Cell Proliferation; Cystitis; Disease M

2019
Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice.
    The Journal of urology, 2015, Volume: 194, Issue:6

    Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Drug Synergism; Hemorrhage; Ifosfamide; Inflixi

2015
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha

2016
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7

    Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Antineoplastic Agents, Alkylating; Antineoplastic

2009
Hind limb ischemic preconditioning induces an anti-inflammatory response by remote organs in rats.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2009, Volume: 42, Issue:10

    Topics: Acute Disease; Animals; Carrageenan; Cystitis; Edema; Hindlimb; Ifosfamide; Indomethacin; Inflammati

2009
Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis;

2011
Interleukin-4 modulates the inflammatory response in ifosfamide-induced hemorrhagic cystitis.
    Inflammation, 2012, Volume: 35, Issue:1

    Topics: Animals; Cyclooxygenase 2; Cystitis; Hemorrhage; Ifosfamide; Interleukin-1beta; Interleukin-4; Male;

2012
In-vitro characterization of the pharmacological effects induced by (-)-α-bisabolol in rat smooth muscle preparations.
    Canadian journal of physiology and pharmacology, 2012, Volume: 90, Issue:1

    Topics: Animals; Carbachol; Cystitis; Disease Models, Animal; Duodenum; Ifosfamide; In Vitro Techniques; Inf

2012
Blockade of TRPA1 with HC-030031 attenuates visceral nociception by a mechanism independent of inflammatory resident cells, nitric oxide and the opioid system.
    European journal of pain (London, England), 2013, Volume: 17, Issue:2

    Topics: Abdomen; Acetanilides; Animals; Antineoplastic Agents, Alkylating; Cell Count; Colitis; Cystitis; Di

2013
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph

2002
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:11

    Topics: Animals; Anti-Inflammatory Agents; Cystitis; Dexamethasone; Disease Models, Animal; Dose-Response Re

2003
Ternatin, a flavonoid, prevents cyclophosphamide and ifosfamide-induced hemorrhagic cystitis in rats.
    Phytotherapy research : PTR, 2004, Volume: 18, Issue:2

    Topics: Animals; Asteraceae; Cyclophosphamide; Cystitis; Flavonoids; Flowers; Hemorrhage; Ifosfamide; Male;

2004
Hypersensitivity pneumonitis associated with the use of trofosfamide.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro

2004
Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1

    Topics: Acrolein; Amifostine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Cystitis; Dose-Response

2007
Cyclooxygenase-2 expression on ifosfamide-induced hemorrhagic cystitis in rats.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:1

    Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; Drug Therapy, Combination; Etorico

2008
[Ifosfamide in the treatment of small cell carcinoma of the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5

    Topics: Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Cystitis; Drug Administration Schedule; Drug T

1983
Ifosfamide: chemotherapy with new promise and new problems for the urologist.
    Urology, 1984, Volume: 24, Issue:5

    Topics: Acetylcysteine; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Ifosfamide; Kidney Neoplasms

1984
The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1980, Volume: 74

    Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Cystitis; Erythrocyte Count; Ifosfamide; Mercaptoe

1980
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Journal of cancer research and clinical oncology, 1981, Volume: 100, Issue:3

    Topics: Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Kidney; Mercaptoethanol; Mesna; Rats; Urina

1981
Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Acrolein; Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Cystitis; Dose

1983
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.
    European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:11

    Topics: Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Kinetics; Male; Rats; Rats, Inb

1981
Prevention of ifosfamide-induced hemorrhagic cystitis by continuous bladder irrigation.
    Urology, 1981, Volume: 18, Issue:3

    Topics: Adult; Aged; Cyclophosphamide; Cystitis; Drug Administration Schedule; Evaluation Studies as Topic;

1981
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.
    European journal of cancer, 1981, Volume: 17, Issue:6

    Topics: Alkylating Agents; Animals; Cyclophosphamide; Cystitis; Dose-Response Relationship, Drug; Female; If

1981
[Combination effect of pirarubicin, ifosfamide, and vincristine sulfate in the treatment of advanced synovial sarcoma--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Cystitis; Doxorubicin; Female; Hemo

1995
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1994, Volume: 35, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu

1994
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo

1993
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Hemorrhage; Huma

1996
Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Archivum immunologiae et therapiae experimentalis, 1997, Volume: 45, Issue:1

    Topics: Administration, Oral; Animals; Cystitis; Edema; Female; Hemorrhage; Ifosfamide; Injections, Intraper

1997
Combined intravenous and oral mesna in outpatients treated with ifosfamide.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:5

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cystitis; Fem

1997
Tumor necrosis factor-alpha and interleukin-1beta mediate the production of nitric oxide involved in the pathogenesis of ifosfamide induced hemorrhagic cystitis in mice.
    The Journal of urology, 2002, Volume: 167, Issue:5

    Topics: Animals; Cystitis; Enzyme Induction; Hemorrhage; Ifosfamide; Interleukin-1; Male; Mice; Nitric Oxide

2002
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
    Onkologie, 1979, Volume: 2, Issue:3

    Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa

1979
Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
    Arzneimittel-Forschung, 1979, Volume: 29, Issue:4

    Topics: Acrolein; Aldehydes; Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Inactivation, Metaboli

1979
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Schweizerische medizinische Wochenschrift, 1979, Dec-08, Volume: 109, Issue:47

    Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Oste

1979
Report on carcinogenesis bioassay of isophosphamide.
    American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6

    Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma

1978
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:3 Pt 1

    Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia;

1990
[Ifosfamide-induced urinary bladder lesion and its inhibition by mesna].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1990, Volume: 96, Issue:2

    Topics: Animals; Cystitis; Dose-Response Relationship, Drug; Female; Ifosfamide; Injections, Intravenous; Ma

1990
Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. An experimental study/short communication.
    Arzneimittel-Forschung, 1989, Volume: 39, Issue:6

    Topics: Acetaldehyde; Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Male; Mesna; Rats

1989
Ifosfamide and mesna.
    The Medical letter on drugs and therapeutics, 1989, Nov-03, Volume: 31, Issue:804

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cystitis; Hemorrhage; Humans; Ifosfamide; Male; Merc

1989
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Comb

1987
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug

1985